Meeting
2020 ASCO Virtual Scientific Program
An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia.
Presenter
James L Januzzi
Massachusetts General Hospital
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Chronic Leukemia—CML
Clinical Trial Registration Number
NCT01207440
Citation
J Clin Oncol 38: 2020 (suppl; abstr 7550)
DOI
10.1200/JCO.2020.38.15_suppl.7550
Abstract #
7550
Poster Bd #
323
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2017 ASCO Annual Meeting
Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).
Speaker: Hagop M. Kantarjian, MD
Videos & Slides
2012 ASCO Annual Meeting
PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.
Speaker: Jorge E. Cortes, MD
Videos & Slides
2024 ASCO Quality Care Symposium
A prospective, longitudinal study of health-related quality of life and contributing factors and its impact on medication adherence to oral anticancer agents in real-world patients with leukemia.
Speaker: Benyam Muluneh, PharmD
Videos & Slides
2024 ASCO Annual Meeting
Hematopoietic stem cell transplant for adults with mixed phenotypic acute leukemia.
Speaker: Jennifer Jing Huang, MD, PhD